NCT01685255 / 2012-001472-10: A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy |
|
|
| Terminated | 2 | 83 | Canada, US, Europe, RoW | Epacadostat, INCB024360, tamoxifen | Incyte Corporation | Ovarian Cancer, Genitourinary (GU) Tumors | 10/14 | 10/14 | | |
SEASCAPE, NCT02575807: Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer |
|
|
| Terminated | 1/2 | 35 | Canada, US | CRS-207, Live, attenuated double-deleted Listeria monocytogenes (LADD), Epacadostat, INCB024360, IDO, Pembrolizumab, Keytruda®, Pembro | Aduro Biotech, Inc., Incyte Corporation | Platinum-resistant Ovarian Cancer, Platinum-resistant Fallopian Cancer, Platinum-resistant Peritoneal Cancer | 04/18 | 05/18 | | |
